Recent Transactions and Developments -Schedule of Calculation of Gain (Details) - USD ($) $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Mar. 31, 2024 |
Dec. 31, 2023 |
Dec. 14, 2023 |
|
| Asset Acquisition [Line Items] | |||||
| Gain on sale of Telavant net assets | $ 0 | $ 110,387 | $ 5,348,410 | ||
| Roche Transaction | |||||
| Asset Acquisition [Line Items] | |||||
| Upfront cash payment | $ 7,100,000 | $ 7,100,000 | |||
| Roche Transaction | RSL | |||||
| Asset Acquisition [Line Items] | |||||
| Upfront cash payment | 5,234,373 | $ 5,200,000 | |||
| Carrying amount of noncontrolling interest derecognized | 87,500 | ||||
| Total consideration | 5,321,873 | ||||
| Assets sold | 3,253 | ||||
| Liabilities transferred | 29,790 | ||||
| Net liabilities sold | (26,537) | ||||
| Gain on sale of Telavant net assets | $ 5,348,410 | ||||